Vitamin D and parathyroid hormone in general populations: Understandings in 2009 and applications to chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 9, 2009, Pages 1508-1514

  Johal, Manraj ^a   Levin, Adeera ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIFEDIOL; CALCITRIOL; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; RENIN; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

CHRONIC KIDNEY DISEASE; FRACTURE; HEALTH STATUS; HIGH RISK POPULATION; HORMONE ACTION; HUMAN; HYPERTENSION; NEOPLASM; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PREVALENCE; PROTEIN FUNCTION; RENAL REPLACEMENT THERAPY; REVIEW; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

AVITAMINOSIS; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; CHRONIC DISEASE; DIETARY SUPPLEMENTS; HUMANS; KIDNEY DISEASES; PARATHYROID HORMONE; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RECEPTORS, CALCITRIOL; REFERENCE VALUES; RENIN; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TERMINOLOGY AS TOPIC; VITAMIN D;

EID: 73249118949     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02160309     Document Type: Review

References (38)

1. Holick MF: Vitamin D deficiency. N Engl J Med 357: 266, 2007
2. Hsu JJ, Tintut Y, Demer LL: Vitamin D and osteogenic differentiation in the artery wall. Clin J Am Soc Nephrol 3: 1542-1547, 2008
3. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P: Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 70: 345-350, 2006
4. Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, DeLuca HF, Drezner MK: Assay variation confounds the diagnosis of hypovitaminosis D: A call for standardization. J Clin Endocrinol Metab 89: 3152-3157, 2004
5. KDIGO Clinical Practice Guidelines for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease Related Mineral and Bone Disorders (CKD-MBD). Available at: http://www.kdigo.org/clinical-practice- guidelines-1.php. Accessed March 18, 2009
6. Fuleihan GE, Klerman EB, Brown EN, Choe Y, Brown EM, Czeisler CA: The parathyroid hormone circadian rhythm is truly endogenous: A General Clinical Research Center study. J Clin Endocrinol Metab 82: 281-286, 1997
7. Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE: Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 86: 3086-3090, 2001
8. Holmes DT, Levin A, Forer B, Rosenberg F: Preanalytical influences on DPC IMMULITE 2000 intact PTH assays of plasma and serum from dialysis patients. Clin Chem 51: 915-917, 2005
9. Holick MF: Vitamin D and sunlight: Strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol 3: 1548-1554, 2008
10. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF: The role of vitamin D in cancer prevention. Am J Public Health 96: 252-261, 2006
11. Zmuda JM, Cauley JA, Ferrell RE: Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev 22: 203-217, 2000
12. Slatter ML, Yakamoto K, Hoffman M, Neuhausen S: Variants of the VDR gene and risk of colon cancer. Cancer Causes Control 12: 359-364, 2001
13. Visser M, Deeg DJ, Lips P: Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 88: 5766-5772, 2003
14. Touyz RM: Molecular and cellular mechanisms in vascular injury in hypertension: Role of angiotensin II-Editorial review. Curr Opin Nephrol Hypertens 14: 125-131, 2005
15. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ: Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 158: 531-537, 2004
16. Llewellyn DJ, Langa KM, Lang IA: Serum 25-hydroxyvitamin D concentration and cognitive impairment. J Geriatr Psychiatry Neurol February 4, 2009 [epub ahead of print]
17. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96: 1755-1760, 1997
18. Resnick LM, Müller FB, Laragh JH: Calcium-regulating hormones in essential hypertension: Relation to plasma renin activity and sodium metabolism. Ann Intern Med 105: 649-654, 1986
19. Posner GH, Crawford KR, Yang HW, Kahraman M, Jeon HB, Li H, Lee JK, Suh BC, Hatcher MA, Labonte T, Usera A, Dolan PM, Kensler TW, Peleg S, Jones G, Zhang A, Korczak B, Saha U, Chuang SS: Potent, low-calcemic, selective inhibitors of CYP24 hydroxylase: 24-Sulfone analogs of the hormone 1alpha,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 89-90: 5-12, 2004
20. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 104: 16810-16815, 2007
21. Forman JP, Bischoff-Ferrari HA, Willett WC, Stampfer MJ, Curhan GC: Vitamin D intake and risk of incident hypertension: Results from three large prospective cohort studies. Hypertension 46: 676-682, 2005
22. De Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS: 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 50: 69-77, 2007
23. Trivedi DP, Doll R, Khaw KT: Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ 326: 469, 2003
24. Shinchuk L, Holick MF: Vitamin D and rehabilitation: Improving functional outcomes. Nutr Clin Pract 22: 297-304, 2007
25. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP: Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr 85: 1586-1591, 2007
26. Agarwal R, Acharya M, Tian J, Hippensteel RI, Melnick JZ, Qiu P, Williams L, Batlle D: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68: 2823-2828, 2005
27. Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL: Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: An analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 53: S3-S10, 2009
28. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
29. Gutiérrez OM, Isakova T, Andress DL, Levin A, Wolf M: Prevalence and severity of disordered mineral metabolism in blacks with chronic kidney disease. Kidney Int 73: 956-962, 2008
30. Levin A, Guiterrez W, Andress D, Wolf M: Deficiencies of Vitamin D are associated with inflammation and albuminuria. J Am Soc Nephrol 18: 527A, 2007
31. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C: Viatmin D levels and patient outcome in chronic kidney disease. Kidney Int 75: 88-95, 2008
32. Shoben AB, Rudser KD, De Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19: 1613-1619, 2008
33. Andrade J, Er L, Ignaszewski A, Levin A: Exploration of Association of 1,25-OH2D3 with augmentation index, a composite measure of arterial stiffness. Clin J Am Soc Nephrol 3: 1800-1806, 2008
34. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kroeneberg F, MMKD Study Group: Fibroblast growth factor 23 (FGF 23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2601-2608, 2007
35. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
36. Drüeke TB, Prié D: Klotho spins the thread of life: What does Klotho do to the receptors of fibroblast growth factor-23 (FGF23)? Nephrol Dial Transplant 22: 1524-1526, 2007
37. Medici D, Razzaque MS, DeLuca S, Rector TL, Hou BK, Goetz R, Mohammadi M, Kuro-o M, Olsen M, Lanske BR: FGF-23: Klotho signalling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol 182: 459-465, 2008
38. KDOQI clinical practice guidelines for bone metabolism and disease in CKD. Am J Kidney Dis 38: S1-S201, 2003